ACXP - Acurx Pharmaceuticals, Inc.


0.4046
0.003   0.717%

Share volume: 82,898
Last Updated: 04-25-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%

$0.40
0.00
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
46%
Profitability 35%
Dept financing 40%
Liquidity 39%
Performance 60%
Company vs Stock growth
vs
Performance
5 Days
4.55%
1 Month
-0.93%
3 Months
-47.93%
6 Months
-78.59%
1 Year
-81.53%
2 Year
-86.47%
Key data
Stock price
$0.40
P/E Ratio 
0.00
DAY RANGE
$0.40 - $0.41
EPS 
-$0.87
52 WEEK RANGE
$0.30 - $3.32
52 WEEK CHANGE
-$81.53
MARKET CAP 
13.751 M
YIELD 
N/A
SHARES OUTSTANDING 
16.245 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$91,520
AVERAGE 30 VOLUME 
$138,911
Company detail
CEO: David P. Luci
Region: US
Website: www.acurxpharma.com
Employees: 3
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria.

Recent news

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025. This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This is the latest in the series of granted patents and pending patent applications that Acurx has filed to p

Read more

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman - as Sponsored Programming

New to The Street debuts its inaugural restaurant segment featuring BlackBarn with owner and chef John Doherty NEW YORK CITY, NY / ACCESS Newswire / April 12, 2025 /New to The Street, a leading financial media TV series, is excited to announce its ...

Read more

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman — as Sponsored Programming

BlackBarn Restaurant NYC on 26th street The premiere restaurant segment with Owner and Head Chef John Doherty NEW YORK CITY, NEW YORK / ACCESS Newswire / April 11, 2025 /New to The Street, a leading financial media TV series, is excited to announce ...

Read more